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Intraplaque hemorrhage frequently occurs in atherosclerotic plaques resulting in cell-free hemoglobin, which is oxidized to ferryl
hemoglobin (FHb) in the highly oxidative environment. Osteoclast-like cells (OLCs) derived from macrophages signify a
counterbalance mechanism for calcium deposition in atherosclerosis. Our aim was to investigate whether oxidized hemoglobin
alters osteoclast formation, thereby affecting calcium removal from mineralized atherosclerotic lesions. RANKL- (receptor
activator of nuclear factor kappa-Β ligand-) induced osteoclastogenic differentiation and osteoclast activity of RAW264.7 cells
were studied in response to oxidized hemoglobin via assessing bone resorption activity, expression of osteoclast-specific genes,
and the activation of signalization pathways. OLCs in diseased human carotid arteries were assessed by immunohistochemistry.
FHb, but not ferrohemoglobin, decreased bone resorption activity and inhibited osteoclast-specific gene expression (tartrate-
resistant acid phosphatase, calcitonin receptor, and dendritic cell-specific transmembrane protein) induced by RANKL. In
addition, FHb inhibited osteoclastogenic signaling pathways downstream of RANK (receptor activator of nuclear factor kappa-
Β). It prevented the induction of TRAF6 (tumor necrosis factor (TNF) receptor-associated factor 6) and c-Fos, phosphorylation
of p-38 and JNK (c-Jun N-terminal kinase), and nuclear translocation of NFκB (nuclear factor kappa-Β) and NFATc1 (nuclear
factor of activated T-cells, cytoplasmic 1). These effects were independent of heme oxygenase-1 demonstrated by knocking
down HO-1 gene in RAW264.7 cells and in mice. Importantly, FHb competed with RANK for RANKL binding suggesting
possible mechanisms by which FHb impairs osteoclastic differentiation. In diseased human carotid arteries, OLCs were
abundantly present in calcified plaques and colocalized with regions of calcium deposition, while the number of these cells were
lower in hemorrhagic lesions exhibiting accumulation of FHb despite calcium deposition. We conclude that FHb inhibits
RANKL-induced osteoclastic differentiation of macrophages and suggest that accumulation of FHb in a calcified area of
atherosclerotic lesion with hemorrhage retards the formation of OLCs potentially impairing calcium resorption.
1. Introduction
Cardiovascular disease is the leading cause of death world-
wide [1] and vascular calcification is one of the independent
risk factors associated with such morbidity and mortality
[2–5]. Pathogenesis of vascular calcification is an active, finely
tuned process with many similarities to the mechanism of
skeletal bone formation [6]. In the bone, mineral deposition
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by osteoblasts and bone resorption by osteoclasts (OCs) are
synchronized processes [7]. Disruption of the balance
between osteoblast and OC activity may have pathological
consequences such as osteoporosis or osteopetrosis [8, 9].
OCs are multinucleated cells derived from monocyte/-
macrophage lineage specialized for bone resorption [10].
The differentiation of macrophages to OCs requires macro-
phage/monocyte colony-stimulating factor-1 (M-CSF) and
the receptor activator of nuclear factor kappa-Β ligand
(RANKL) [11]. RANKL interacts with the receptor activator
of nuclear factor kappa-B (RANK) activating downstream
genes including tumor necrosis factor (TNF) receptor-
associated factor 6 (TRAF6) [12], c-Jun N-terminal kinase
(JNK) [13], p38 [14], nuclear factor-kappa B (NFκB) [15],
c-Fos [16], and nuclear factor of activated T-cells, cyto-
plasmic 1 (NFATc1) [17]. NFATc1 plays a pivotal role
in OC maturation by regulating the expression of OC-
specific genes, such as dendritic cell-specific transmem-
brane protein (DC-STAMP), tartrate-resistant acid phos-
phatase (TRAP), cathepsin K (CatK), and calcitonin
receptor (CTR) [18–22].
RANKL and M-CSF are both expressed in calcifying ves-
sels [23, 24]. In atherosclerotic plaques, calcification and
bone formation are common phenomena characterized by
the presence of vascular smooth muscle cells (VSMCs), oste-
oblasts, and osteoclast-like cells (OLCs) [25]. OLCs differen-
tiate from infiltrating macrophages and colocalize with
cholesterol deposition and mineralization [26]. An intriguing
model has been raised by Doherty and coworkers suggesting
that arterial calcium deposits represent a unique scenario
which might favor the formation of OLCs from hematopoi-
etic precursors possibly limiting calcification in atherosclero-
sis [27]. This hypothesis is further supported by the fact that
Runx2, a key transcription factor that induces transition of
VSMCs to osteoblast-like cells, directly binds to the promoter
of RANKL and activates its expression leading to mineral
deposition by VSMCs-derived osteoblasts and mineral
resorption by OLCs [28]. Within the intramural compart-
ment of the arteries, OLCs might degrade mineral deposits,
thereby attenuating calcification and counterbalancing the
activity of VSMC-derived osteoblasts [26]. The imbalance
between bone formation by VSMC-derived osteoblasts and
bone resorption by OLCs triggers pathological calcification
process in the vessel walls.
Li and coworkers have described that complicated pla-
ques with hemorrhage are characterized by a highly oxidative
scenario creating a “death zone” for red blood cells (RBCs)
[29]. RBCs in these death zones are lysed, and free Hb is
subjected to rapid oxidation forming met-hemoglobin
(MetHb, Fe3+) and ferryl hemoglobin (FHb, Fe4+ = O2−).
Importantly, oxidation of Hb also leads to the release of
heme moieties [30]. A significant body of evidence suggests
that MetHb and FHb are present in hemorrhagic compli-
cated plaques [31]. Our research group previously reported
that FHb is a potent proinflammatory agonist in endothe-
lial cells that induces morphological changes [32], increases
monolayer permeability, and enhances monocyte adhesion
[33]. These data suggest that oxidized Hb forms are
involved in the pathogenesis of atherosclerosis.
The massive Hb content of hemorrhagic atheromas
prompted us to examine whether the compensatory effect
of OLCs in vascular calcification is influenced by products
of Hb oxidation. The purpose of this study was to investigate
the role of oxidized Hb in OC formation and resorption of
calcium in calcified atheromas.
2. Materials and Methods
2.1. Study Approval. Carotid arteries were obtained from
patients who underwent carotid endarterectomies from
the Department of Surgery at the University of Debrecen.
The collection was approved by the Scientific and Research
Ethics Committee of the Scientific Council of Health of the
Hungarian Government under the registration number of
DE OEC RKEB/IKEB 3712-2012. Written informed con-
sents were received from each participant. The study proto-
col conforms to the ethical guidelines of the 1975
Declaration of Helsinki.
2.2. Cell Culture and Reagents. Murine macrophage
RAW264.7 cells were obtained from ATCC (Manassas, VA,
USA). RANKL was purchased from Miltenyi Biotec (Ber-
gisch Gladbach, Germany). Unless otherwise mentioned,
all other reagents were obtained from Sigma (Saint Louis,
MO, USA). Cells were cultured in DMEM containing
10% FBS, 100U/mL penicillin, 100μg/mL streptomycin
and neomycin, and 1mM of sodium pyruvate (culture
medium). Heme was dissolved in 20mM NaOH.
2.3. In vitro Osteoclastogenesis. Cells (2 × 104/cm2) were
seeded onto 24-well plates and cultured in growth medium
supplemented with RANKL (50ng/mL) (osteoclastogenic
medium) in the presence or absence of Hb (10μmol/L heme
group), MetHb (10μmol/L heme group), and FHb
(10μmol/L heme group) as indicated. The medium was
changed every 2-3 days.
2.4. Immunohistochemistry. Carotid artery specimens were
fixed with PBS formaldehyde (4%) solution at pH7.4 for 1
to 3 days based on the size of the sample. After fixation,
calcified samples were decalcified with 1.0mol/L EDTA/Tris
buffer. Paraffin-embedded 5-μm-sections were deparaffa-
nized in xylenes, rehydrated in a series of ethanol rinses from
100% to 70%, then washed with distilled water. Antigen
retrieval was performed in RE7119 buffer (Leica, Wetzlar,
Germany) at 95°C for 30 minutes. Sections were allowed to
cool slowly, washed in distilled water, and incubated in
0.5% H2O2 for 10 minutes. For immunohistochemistry, sam-
ples were incubated with Dako EnVision FLEX Peroxidase-
Blocking Reagent (Dako, Glostrup, Denmark) for 5min in
a wet chamber. Slides were then washed with EnVisionTM
FLEX Wash Buffer, Tris-buffered saline solution containing
Tween 20, and pH7.6 (±0.1). Serial sections slides were incu-
bated with antibodies against TRAcP (Roche, Mannheim,
Germany, ready-to-use) or cathepsin K (Abcam, Cambridge,
UK) at a dilution of 1 : 200, or CD68 (Roche, ready-to-use) or
anti-FHb polyclonal antibody at a dilution of 1 : 50 using the
ultraview universal DAB detection kit following the manu-
facturer’s instructions. The intensity and distribution of
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TRAcP, cathepsin K, CD68, and FHb specific immunostain-
ing were assessed by light microscopy (Leica DM2500 micro-
scope, DFC 420 camera and Leica Application Suite V3
software, Leica). Samples were counterstained with Gill’s
Hematoxylin solution (105175 Merck Millipore, Billerica,
MA, United States), rinsed in running tap water for 5min
and dehydrated through 95% ethanol for 1min and
100% ethanol for 2 × 3min followed by a clearing step in
xylene for 2 × 5min. The sections were then mounted
using mounting media.
2.5. Isolation of Bone Marrow Monocytes. Bone marrow-
derived monocytes (BMDMs) were isolated from wild type
and heme oxygenase-1- (HO-1-) deficient mice (-/-) as
described earlier [34]. BMDMs were treated for 5 days with
RANKL (100 ng/mL) and MCS-F (50ng/mL) in the presence
and absence of FHb (10μmol/L).
2.6. Hemoglobin Preparation. Hb of different redox states,
that is, (Fe2+) oxyHb, (Fe3+) MetHb, and (Fe4+) FHb, was
prepared as described [32]. Briefly, Hb was isolated from
fresh blood drawn from healthy volunteers using ion-
exchange chromatography on a DEAE Sepharose CL-6B col-
umn. To generate MetHb, purified Hb was incubated with a
1.5-fold molar excess of K3Fe (CN)6 over heme for 30min
at 25°C. FHb was obtained by incubation of Hb for 1 h at
37°C with a 10 : 1 ratio of H2O2 to heme. Then, MetHb and
FHb were dialyzed against saline (3 times for 3 hours at
4°C) and concentrated using Amicon Ultra centrifugal filter
tubes (10,000 MWCO, Millipore Corp., Billerica, MA,
USA). Aliquots were snap-frozen in liquid nitrogen and
stored at −80°C. The purity of each Hb preparation was eval-
uated by SDS-PAGE followed by staining with the ProteoSil-
ver Plus Silver Staining Kit. The purity of Hb preparations
was above 99.9%. Hb concentrations were calculated as
described by Winterbourn [35].
2.7. Spectral Scan of Human Carotid Arteries.Healthy carotid
arteries, calcified atheromas, and calcified atheromas with
hemorrhage were ground in liquid nitrogen, homogenized
in phosphate-buffered saline (PBS, pH7.4) followed by
sonication on ice 3 times for 5 sec. Samples were then
spinned at 12,000 × g for 20 minutes at 4°C, and the
upper phase was measured by UV-visible spectra recorder
(Beckman DU-800 spectrophotometer) from 500nm to
700nm wavelengths.
2.8. Tartrate-Resistant Acid Phosphatase (TRAP) Staining.
For TRAP staining, cells were cultured in osteoclastogenic
medium for 5 days. Osteoclastic differentiation was evalu-
ated by TRAP staining using a leukocyte acid phospha-
tase kit according to the manufacturer’s instructions.
TRAP+multinucleated (more than 3 nuclei/cell) cells were
identified as OCs. The areas of osteoclasts were measured
by the ImageJ software.
2.9. Bone Resorption Assay. Bone resorptive activity of
formed OCs was measured by bone resorption assay using
Corning Osteo Assay Surface plate according to the manu-
facturer’s instructions. The areas of resorption pit were deter-
mined with the ImageJ software.
2.10. Quantitative Reverse Transcription-Polymerase Chain
Reaction. Total RNA was isolated using TRI Reagent (Zymo
Research, Irvine, CA, USA), reverse transcribed with
High-Capacity cDNA kit (Applied Biosystems, Foster
City, CA), and real-time polymerase chain reactions were
performed using fluorescent TaqMan probes. TaqMan gene
expression assays for CTR (Mm00432282_m1), DC-STAMP
(Mm04209236_m1), NFATc1 (Mm00479445_m1), HO-1
(Mm00516005_m1), RANK (Mm00437132_m1), and β-actin
(Mm00607939_s1) were purchased from Thermo Scientific
(Waltham, MA, USA). To measure the mRNA levels, the
20μL reaction mixture included 10μL of reverse transcribed
sample (4ng/μL) and 10μL Master Mix (Thermo Scientific)
containing 1μL TaqMan Assay (20×). PCRs were carried out
using the iCycler iQ Real-Time PCR System (Bio-Rad Labora-
tories, Hercules, CA). Results were normalized by β-actin
mRNA levels.
2.11. Cell Proliferation Assay. RAW264.7 cells were cultured
in 24-well plates in growth medium and osteoclastogenic
medium alone or supplemented with FHb for 1-4 days. The
amount of viable cells was assessed by MTT assay.
2.12. Cytoplasmic and Nuclear Protein Extraction. Cells were
grown in 6-well plates in growth medium or osteoclastogenic
medium in the presence or absence of FHb for indicated
time. Cells were washed three times with PBS and lysed with
Harvest buffer (10mM HEPES pH7.9, 50mM NaCl, 0.5M
sucrose, 0.5% Triton X-100, and protease inhibitors). After
10min of incubation on ice, samples were spinned at
1000 × g for 5min and supernatants were collected as
cytosolic fraction. Pellets containing the nuclear fraction
were washed three times with wash buffer (10mM HEPES
pH7.9, 10mM KCl, 0.1% NP-40, and protease inhibitors)
and solubilized in nuclear protein extraction buffer
(50mM Tris pH7.5, 150mM NaCl, 0.5% sodium deoxy-
cholate, 0.1% SDS, and protease inhibitors).
2.13. Immunofluorescence Staining. Cells were treated as
described above with RANKL in the presence or absence of
FHb. Cells were fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS) pH7.4 for 15 minutes. Cov-
erslips were washed with PBS and samples were blocked with
5% goat serum in PBS supplemented with 0.3% Triton X-100
for 60min. Samples were then incubated with primary anti-
body against NFATc1 (Novus Biologicals, Littleton, CO,
USA) at a 1 : 250 dilution overnight at 4°C in antibody dilu-
tion buffer (1% BSA in PBS supplemented with 0.3% Triton
X-100). The secondary antibody was a goat anti-mouse IgG
conjugated to Alexa Fluor® 488 (Thermo Scientific) used at
a 1 : 500 dilution in antibody dilution buffer and incubated
for 60min at room temperature. Nuclei were visualized with
Hoechst. Nuclear translocation was investigated with TCS
SP8 STED microscope using the Leica Application Software
X (Leica, Mannheim, Germany).
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2.14. Western Blot. HO-1, CTR, DC-STAMP, c-Fos, TRAF6,
RANK expression, phosphorylation of p38, JNK, and cell-
bound RANKL were analyzed by immunoblotting from
whole-cell lysates with anti-HO-1 antibody (Proteintech,
Manchester, UK) at 1 : 2000 dilution or anti-RANK antibody
(Santa Cruz Biotechnologies, Santa Cruz, CA, USA) at 1 : 250
or anti-RANKL antibody (Abcam, Cambridge, UK) at 1 : 100
dilution or anti-CTR antibody (Proteintech) or anti-DC-
STAMP antibody (Sigma) or anti-c-Fos antibody (Cell
Signaling) or anti-TRAF6 antibody (Proteintech, Manches-
ter, UK) or anti-phospho-p38 antibody (Cell Signaling,
Danvers, MA, USA) or anti-p38 antibody (Cell Signaling)
or anti-phospho-JNK antibody(Cell Signaling) or anti-JNK
antibody(Cell Signaling) at 1 : 1000 dilution followed by
HRP-labeled anti-mouse or anti-rabbit IgG antibody
(Amersham Biosciences, Little Chalfont, UK). For CTR
and DC-STAMP analysis, proteins were transferred with
Dunn Carbonate Buffer. Nuclear translocation of NFATc1
and NFκB were investigated using nuclear and cytosolic
fractions with anti-NFATc1 antibody (Novus Biologicals)
or anti-NFκB antibody (Cell Signaling) at 1 : 500 dilution.
Antigen-antibody complexes were visualized with the
horseradish peroxidase chemiluminescence system (Amer-
sham Biosciences). After detection, membranes were
stripped and reprobed for GAPDH (Novus Biologicals) at
1 : 3000 or HSP90 (Cell Signaling) at 1 : 1000 or Lamin B1
(Proteintech) at 1 : 2000 dilution. Quantification of chemilu-
minesce was done by using the ImageJ software.
2.15. HO Activity Assay. Cells grown on 6-well plates were
washed twice with Hank’s Balanced Salt Solution (HBSS),
and scraped and centrifuged at 2000 × g for 15min at 4°C.
Cells were re-suspended in 300μL of potassium phosphate
(100mmol/L (pH7.4)) buffer containing 2mmol/L MgCl2,
frozen and thawed three times, and sonicated and centri-
fuged at 18,000 × g for 10min at 4°C. Supernatants contain-
ing cell microsomes were used to measure HO activity as
described previously [36]. HO activity is expressed as pmol
bilirubin formed/mg cell protein per 60min.
2.16. HO-1 Short-Interfering RNA (siRNA) Transfection.
Small interfering RNA (siRNA) specific to HO-1 and nega-
tive control siRNA were obtained from Ambion (Austin,
TX, USA). Transfection of siRNA into RAW264.7 cells was
performed using the Oligofectamine Reagent (Invitrogen,
Carlsbad, CA, USA). Briefly, cells were plated in antibiotic-
free DMEM and cultured for 6 h. HO-1 siRNA at 40 nmol/L
and transfection reagent complex were added to the cells in
serum-free medium OptiMEM (Gibco, Thermo Scientific)
for 16 h. Fresh normal growth medium was added then and
the cells were incubated for another 8 h.
2.17. Detection of Crosslinked Hb by Western Blot. The
detection of crosslinked Hb in three healthy carotid arteries,
three atheromas, and three complicated carotid lesions with
hemorrhage by Western blot was performed as described in
our previous study [31] using HRP-conjugated goat anti-
human Hb polyclonal antibody (ab19362-1 Abcam, Cam-
bridge, UK) at a dilution of 1 : 15000.
2.18. Expression of Recombinant Mouse RANKL with 6× His
Tag. For in vitro interaction assay, recombinant mouse
RANKL with N-terminal 6× His tag was expressed in E. coli
Rosetta 2. Total mRNA was isolated from the lung tissue of
C57BL mice, reverse transcribed, cloned into pTriex-4 Neo,
and verified by sequencing. To express His-tagged RANKL,
E. coli Rosetta 2 cells were transformed and cultured in
Luria-Bertani medium containing 100μg/mL carbenicilllin
at 30°C 250 rpm until OD600 = 0:5, then protein expression
was induced with 1mM Isopropyl β-D-1-thiogalactopyrano-
side (IPTG) followed by shaking at 250 rpm at 30°C for 3 h.
Cells were then pelleted at 3990 × g at room temperature
for 15min and lysed with cold lysis buffer pH8.0 (50mM
NaH2PO4, 300mM NaCl, 1% Triton X-100, protease inhibi-
tors, and 1mg/mL lysozyme). His-tagged RANKL was puri-
fied using Protino Ni-TED 150 packed columns according
to the manufacturer’s guide. Endotoxin contamination was
removed using Pierce™ High Capacity Endotoxin Removal
Resin (Thermo). The quality of recombinant RANKL was
analyzed by Coomassie staining and immunoblot. Recombi-
nant His-tagged RANKL was effective to induce OC forma-
tion demonstrated by TRAP staining.
2.19. In Vitro RANK-RANKL Interaction Assay. To study the
inhibitory effect of FHb on RANK-RANKL interaction in a
test tube experiment, RANK was purified from RAW cells
using immunoprecipitation. Briefly, cells were lysed with
cold lysis buffer containing 50mM Tris pH7.5, 150mM
NaCl, 2× protease inhibitor cocktail, and 1% Triton X-100;
incubated on ice for 10min; and clarified by centrifugation
at 14000 × g for 10min at 4°C. Supernatants were then gently
rocked at 4°C with 15μg of RANK antibody overnight, then
antigen-antibody complexes were coincubated with pre-
washed protein A/G magnetic beads (Thermo Scientific) for
60min at room temperature. Beads were then washed three
times with cold wash buffer containing detergent (50mM
Tris pH7.5, 150mM NaCl, 0.05% Igepal CA630, and prote-
ase inhibitors), then three times with wash buffer without
detergent (50mM Tris pH7.5, 150mM NaCl), and coincu-
bated with 1μg RANKL or 1μg RANKL and 10μM FHb at
room temperature for 60min. Beads were then washed three
times with 50mM Tris pH7.5 and 150mM NaCl, and sam-
ples were eluted with 2 × SDS sample buffer without reducing
agent at 50°C for 10min, supplemented with 100mM DTT
and subjected to immunoblot analysis.
2.20. Statistical Analysis. Statistical analysis was performed
with GraphPad Prism 5 by one-way ANOVA test followed
by post hoc Bonferroni’s Multiple Comparison test or t test.
A significant value of p < 0:05 was marked with ∗, p < 0:01
with ∗∗, and p < 0:001 was marked with ∗∗∗. Nonsignificant
(ns) differences were also marked. Data are shown as
mean ± SEM.
3. Results
3.1. FHb Inhibits Osteoclastogenesis and OC Bone Resorption
Activity.Macrophages can transform into OCs in response to
RANKL [37, 38]. To investigate the effect of Hbs on RANKL-
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induced osteoclastogenesis, murine macrophage RAW264.7
cells were cultured in osteoclastogenic medium containing
50 ng/mL RANKL in the presence or absence of Hb, MetHb,
or FHb. First, we analyzed the effect of the different Hb forms
on RANKL-induced osteoclastogenesis using TRAP staining
(Figure 1(a)). Heme (50μmol/L), a potent inhibitor of
RANKL-induced osteoclastogenesis, was used as positive
control for inhibition assays. RANKL-induced OC formation
was significantly inhibited either by heme (50μmol/L) or
FHb (10μmol/L heme group), but not by Hb (10μmol/L
heme group) or MetHb (10μmol/L heme group). To quan-
tify OC formation, the areas of TRAP-positive cells were
measured by the ImageJ software (Figure 1(b)). This analysis
revealed that RANKL-induced OC formation was signifi-
cantly (p < 0:001) impaired either by heme or FHb, but not
by Hb or MetHb (Figure 1(b)). Next, we examined whether
FHb inhibits bone resorption activity of OCs (Figure 1(c)).
Our data suggest that both FHb and heme significantly
(p < 0:001) reduced the resorption area of OCs, while neither
Hb nor MetHb influenced bone resorptive activity
(Figures 1(c) and 1(d)). Next, we examined whether a dose-
response relationship exists between FHb concentration
and inhibition of OC differentiation. We showed that FHb
inhibited osteoclastogenesis in a dose-dependent manner,
and as low as 2.5μmol/L FHb significantly prevented OC
formation as evidenced by TRAP staining (Figure 1(e) upper
panel and Figure 1(f)) and bone resorption assay (Figure 1(e)
lower panel and Figure 1(g)). To explore whether this inhib-
itory effect of FHb is associated with its potential cytotoxic
effect, we cultured RAW264.7 cells for 4 days in the presence
or absence of RANKL and FHb. Cell proliferation and viabil-
ity were analyzed with MTT assay at various time points (one
to four days). Our results showed the proliferation of
RAW264.7 cells decreased in response to RANKL as well as
to RANKL+FHb compared with untreated cells; however,
FHb did not affect proliferation compared with RANKL-
treated cells (Supplementary fig. 1A). Next, we explored
whether such decreased proliferation was associated with
apoptotic cell death. Accordingly, we analyzed caspase-3
cleavage as a marker of apoptosis by immunoblot which
showed that apoptotic cell death did not occur during
OC differentiation in response to RANKL and FHb
(Supplementary fig. 1B).
3.2. FHb Downregulates OC-Specific Gene Expression in
Response to RANKL. Osteoclastic differentiation of
macrophages requires changes in protein expression [39];
therefore, we examined the effect of various Hb forms on
the expression of osteoclast-specific markers (CTR, DC-
STAMP, and NFATc1) using quantitative real-time PCR
(qRT-PCR) and immunoblotting. As expected, RANKL sig-
nificantly upregulated CTR (Figure 2(a)) and DC-STAMP
(Figure 2(b)) expression in RAW264.7 cells that was inhib-
ited both by FHb (p < 0:001) and heme (p < 0:001) and, to
a lesser extent, by MetHb (p < 0:01). Importantly, Hb did
not prevent RANKL-induced CTR and DC-STAMP induc-
tion. Significantly, FHb and heme but not Hb and MetHb
blunted NFATc1 (p < 0:001) expression induced by RANKL
(Figure 2(c)).
3.3. Inhibitory Effect of FHb on Osteoclastogenesis Is
Independent of HO-1. We have previously described that
FHb induces HO-1 in endothelial cells [33] and it has been
reported that upregulation of HO-1 by heme inhibits OC for-
mation and bone resorption in vitro [40]. Therefore, we
tested whether HO-1 mediates the inhibitory effect of FHb
on OC formation. As shown in Figure 3, FHb, similar to
heme, significantly induced HO-1 expression both at mRNA
and protein levels (Figures 3(a)–3(c)) and increased HO
enzyme activity (Figure 3(d)) in RAW264.7 cells.
We knocked down HO-1 expression by HO-1-specific
siRNA and analyzed osteoclastogenesis in response to
RANKL and FHb. Surprisingly, FHb prevented RANKL-
induced OC formation in HO-1-silenced cells similar to the
controls that was demonstrated by TRAP staining
(Figures 4(a) and 4(c)) and bone resorption assay
(Figures 4(b) and 4(d)). Silencing HO-1 expression was con-
firmed by immunoblotting (Figure 4(e)). To further verify
our results at the molecular level, CTR expression—as OC
marker—was monitored by q-RT-PCR in HO-1-knocked
down cells after RANKL treatment.We showed that irrespec-
tive of the degree of HO-1 expression, administration of FHb
significantly decreased RANKL-mediated CTR mRNA
expression (Figure 4(f)).
We also assessed the ability of FHb to mitigate osteoclas-
togenesis in BMDMs obtained from wild-type (HO-1+/+) and
HO-1 knock out (HO-1−/−) mice (n = 4). FHb significantly
induced HO-1 mRNA expression in BMDMs derived from
HO-1+/+ mice; however, no HO-1 expression was detected
in BMDMs isolated from HO-1 knock out HO-1−/− mice
(Figure 4(g)). Importantly, FHb inhibited RANKL-induced
CTR expression in both HO-1+/+ and in HO-1−/− BMDMs
(Figure 4(h)). These results support that the inhibitory effect
of FHb on osteoclastogenesis is independent of HO-1
expression.
3.4. FHb Blocks RANK-RANKL Interaction. The formation of
OCs requires RANKL attachment to its receptor RANK [41].
In addition, RANKL directly induces RANK expression [42].
To decipher the molecular mechanism by which FHb inhibits
OC formation, we tested whether FHb influences RANKL-
induced RANK expression. We demonstrated that FHb
significantly attenuated RANK expression in response to
RANKL both at mRNA (Figure 5(a)) and protein levels
(Figures 5(b) and 5(c)). To gain a more mechanistic insight
into the inhibitory effect of FHb on OC formation, we ana-
lyzed whether FHb inhibits the RANK-RANKL interaction
by measuring the amount of cell-associated RANKL by
immunoblot. We showed that the association of exogenous
RANKL to cells was markedly decreased when FHb was pres-
ent in the experimental medium (Figures 5(d) and 5(e)). To
further verify this observation, we developed a recombinant
His-tagged RANKL to study RANK-RANKL interaction in
test tube experiments. The purity of our in-house His-
tagged RANKL was validated by Coomassie staining and
immunoblot (Supplementary fig. 2A). We demonstrated that
His-tagged RANKL effectively induced OC formation in
RAW cultures demonstrated by TRAP staining (Supplemen-
tary fig. 2B). In the test tube experiments, RANK was
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Figure 1: Continued.
6 Oxidative Medicine and Cellular Longevity
immunoprecipitated from RAW264.7 cell lysates and coin-
cubated with His-tagged recombinant RANKL (1μg) in the
presence or absence of FHb. The association of recombinant
RANKL with RANK was analyzed by immunoblot. Test tube
experiments corroborated our findings in cell cultures that
FHb inhibited RANK-RANKL interaction (Figure 5(f)).
These data suggest that the inhibitory effect of FHb on RANK
expression and osteoclastic transformation of RAW264.7
cells were mediated by inhibition of the direct interaction
between RANK and RANKL.
3.5. FHb Inhibits RANKL-Induced Signaling Involved in OC
Differentiation. RANK-RANKL interaction initiates a series
of signaling events leading to OC formation from macro-
phages [43]. This includes TRAF6 which activates down-
stream pathways, such as NFκB, JNK, p38, c-Fos, and
NFATc1, which are all crucial factors in OC differentiation.
Here, we showed that RANKL induced TRAF6 expression
(Figure 6(a)), p38 and JNK activation (Figure 6(b)), c-Fos
expression (Figure 6(c)), nuclear translocation of NFκB
(Figure 6(d)), and NFATc1 (Figures 6(e)–6(h)). Impor-
tantly, the exposure of cells to FHb prevented the induction
of TRAF6 and c-Fos, phosphorylation of p38 and JNK,
and nuclear translocation of NFκB and NFATc1. These
results corroborate our hypothesis that FHb inhibits
RANK-RANKL interaction and its subsequent signaling
pathways, thereby preventing OC differentiation from
macrophages.
3.6. Oxidation of Hb Occurs in Calcified Lesions with
Hemorrhage. Our previous studies revealed that complicated
lesions with hemorrhage contain oxidized forms of hemoglo-
bin [31] which is also corroborated by our current study.
Spectrophotometric analysis of the human vessel samples
showed that oxidized Hb was present in the calcified
atheromas with hemorrhage, while healthy arteries and calci-
fied lesions did not contain oxidized Hb (Figure 7(a)). We
observed the marked accumulation of crosslinked Hb
dimers, tetramers, and multimers in hemorrhagic calcified
plaques reflecting that Hb oxidation are extensive in these
lesions compared with calcified atheromas without hemor-
rhage or healthy carotid arteries (Figure 7(b)).
3.7. Lack of OLCs Is Associated with the Presence of FHb in
Hemorrhagic Calcified Lesions in Human Vessels. To examine
whether FHb inhibits OLC formation in patients who under-
went carotid endarterectomy, the presence of OLCs was ana-
lyzed in healthy carotid arteries, calcified atheromas, and
calcified atheromas with hemorrhage (Figure 7(c)). Extracel-
lular calcium deposits were present in calcified atheromas
and in calcified atheromas with hemorrhage as evidenced
by Von Kossa staining (row B). The presence of FHb was
prominent in calcified atheromas with hemorrhage while
no positive staining pattern could be seen in carotid arteries
from healthy individuals or calcified lesions without hemor-
rhage (row C). Furthermore, multiple CD68 positive, multi-
nucleated giant cells were detected in calcified lesions while
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Figure 1: FHb inhibits osteoclastogenesis and OCs bone resorption activity in vitro (a) RAW264.7 cells were cultured on 24-well plates in
control growth medium or in osteoclastogenic medium (control growth medium supplemented with 50 ng/mL RANKL) or in
osteoclastogenic medium with heme (50 μmol/L), Hb (10 μmol/L heme group), MetHb (10 μmol/L heme group), or FHb (10 μmol/L heme
group) for 5 days and stained for tartrate-resistant acid phosphatase (TRAP). Representative images of stained microscopic views
(magnification 100×) from three independent experiments are shown. (b) Areas of TRAP-positive multinucleated cells were determined in
ten microscopic field areas and compared with untreated cells. Data are expressed as mean ± SE of three independent experiments. (c)
RAW264.7 cells were cultured on Osteo-Assay Surface plate in control growth medium or in osteoclastogenic medium (control growth
medium supplemented with 50 ng/mL RANKL) or in osteclastogenic medium with heme (50 μmol/L), Hb (10 μmol/L heme group),
MetHb (10 μmol/L heme group), or FHb (10 μmol/L heme group) for 6 days. Representative microscopic pictures of resorbed pits are
shown (magnification 100×). (d) The areas of resorption pits were determined in ten microscopic field areas and compared with untreated
cells. Data are expressed as mean ± SE of three independent experiments. (e) RAW264.7 cells were cultured on 24-well plates in control
growth medium or in osteoclastogenic medium in the absence or presence of FHb (2.5, 5, and 10μmol/L heme group) for 5 days for
tartrate-resistant acid phosphatase (TRAP) staining (upper panel) or on Osteo-Assay Surface plates for bone resorption assay (lower
panel). Representative images of stained microscopic views (magnification 100×) from three independent experiments are shown. The
areas of TRAP positive cells (f) or resorption pits (g) were determined in ten microscopic field areas and compared to untreated cells.
Data are expressed as mean ± SE of three independent experiments.
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the number of these cells was rather limited in calcified pla-
ques with hemorrhage (row D). CD68 positive, multinucle-
ated giant cells were not present in healthy carotid arteries
(row D). Multinucleated giant cells showed the characteris-
tics of OCs demonstrated by TRAP (row E) and CatK (row
F) staining. A number of OLCs positive to TRAP and CatK
staining were identified and were evident around the calcified
area in calcified atheromas suggesting the presence of OLCs
in calcified vessels. In sharp contrast, the number of OLCs
in calcified plaques with hemorrhage was scarce despite the
extensive calcification. These data demonstrate that the
presence of OLCs in calcified atheromas with hemorrhage
is significantly limited when compared to calcified lesions
without hemorrhage.
4. Discussion
The presence of OLCs in the calcified area of atherosclerotic
plaques is well demonstrated [44]. According to the “osteo-
clast theory,” an increased osteoblastic and a reduced osteo-
clastic activity might contribute to intima calcification [45].
Therefore, disturbances in OLC differentiation and activity
in the atherosclerotic plaques might be considered a patho-
genic factor in vessel wall calcification.
Vascular calcification is associated with increased cardio-
vascular morbidity and about one-fifth of the calcified vessels
and valves contain trabecular bone [46]. The molecular
mechanism of arterial calcification resembles bone minerali-
zation sharing a number of similarities [47]. Under
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Figure 2: FHb downregulates OC-specific gene expression in response to RANKL RAW264.7 cells were cultured on 24-well plates in control
growth medium or in osteoclastogenic medium (control growth medium supplemented with 50 ng/mL RANKL) or in osteoclastogenic
medium with heme (50 μmol/L), Hb (10 μmol/L heme group), MetHb (10 μmol/L heme group), or FHb (10 μmol/L heme group). CTR
(a), DC-STAMP (b), and NFATc1 (c) gene expressions were analyzed with quantitative RT-PCR and immunoblot after 5 days for CTR, 4
days for DC-STAMP, and 3 days for NFATc1. qRT-PCR was normalized to β-actin while immunoblot was normalized to GAPDH. Data
are expressed as mean ± SE of three independent experiments.
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homeostatic conditions in bones, mineral deposition by oste-
oblast and resorption mediated by OCs are strictly coupled
resulting in a delicate balance between bone anabolism and
catabolism [48, 49].
The importance of functional OLCs in vascular calcifica-
tion has been documented by several studies. Mice lacking
carbonic anhydrase II, which is essential for bone resorption
activity of OLCs, develop arterial calcification [50]. In addi-
tion, the lack of M-CSF, which is necessary for OLC forma-
tion, promotes vascular calcification in mice possibly due to
the impaired OLC formation [51]. Overall, these findings
suggest that functional OLCs are essential for mineral resorp-
tion in the vasculature, and that lack of OLC activity pro-
motes vascular calcification. Multinucleated, TRAP-positive
cells with typical osteoclastic morphology were identified in
atherosclerotic lesions close to the mineralized areas [26].
This observation was also supported by our present results
in human atherosclerotic carotid arteries demonstrating the
presence of a vast number of OLCs with strong cathepsin K
and TRAP positivity in the vessel wall areas where minerali-
zation occurred. However, the number of OLCs was limited
in the calcified atheromas with hemorrhage that were charac-
terized by the presence of oxidized Hbs, and this observation
supports our hypothesis that FHb abolishes OLCs from hem-
orrhagic, calcified carotid tissues resulting in insufficient
mineral resorption from the vessel wall.
The formation of OLCs in the vasculature is dependent on
RANKL that is abundantly secreted by a number of cell types,
such as VSMCs and endothelial cells [52–54]. Following inter-
action with RANK, RANKL induces the activation of down-
stream signalization, such as tumor necrosis factor (TNF)
receptor-associated factor 6 (TRAF6) [12], c-Jun N-terminal
kinase (JNK) [13], p38 [14], receptor activator of nuclear
factor-kappa B (NFκB) [15], c-Fos [16], and NFATc1.
NFATc1 activates a number of downstream genes such as
CTR, cathepsin K, and TRAP [55]. The pivotal function of
NFATc1 is highlighted by the significant impairment of oste-
oclastogenesis in OC-specific conditional NFATc1-deficient
mice [56]. In addition, NFATc1-deficient embryonic stem
cells are unable to differentiate into OCs in response to
RANKL [55]. In our study, we showed that FHb but not
MetHb or ferrous Hb inhibited the expression of NFATc1.
In addition, the expression of other OC markers, such as
CTR and DC-STAMP, was also alleviated by FHb, and, to a
lesser degree, by MetHb, but not by ferrous Hb. These data
indicate that the inhibitory effect of FHb on osteoclastogenesis
is mediated by the suppression of the key genes involved in
this process. Furthermore, we demonstrated that this
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Figure 3: FHb induces HO-1 expression in RAW264.7 cells. RAW264.7 cells were grown on 24-well plates in control growth media or in
osteoclastogenic media (control growth medium supplemented with 50 ng/mL RANKL) in the absence or presence of heme (50 μmol/L)
or FHb (10 μmol/L heme group) for 5 days. (a) HO-1 mRNA levels were determined by quantitative RT-PCR and normalized to β-actin.
Results are presented as mean ± SE of three independent experiments. (b–c) HO-1 protein expression was detected by Western blot and
normalized to GAPDH after densitometric analysis. A representative image of three independent experiments is shown. (d) HO enzyme
activity was measured as described in Section 2. Results are shown as mean ± SE from three independent experiments.
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Figure 4: Inhibitory effect FHb on osteoclastogenesis is independent of HO-1. RAW264.7 cells were transfected withHO-1 or negative control
siRNA (NC) and maintained in control growth medium or osteoclastogenic media (control growth medium supplemented with 50 ng/mL
RANKL) in the absence or presence of FHb (10 μmol/L heme group). OC formation in wild type, NC siRNA-treated, or HO-1-knocked
down cells were analyzed by TRAP staining (a) or pit formation assay (b). The areas of TRAP positive cells (c) or resorption pits (d) were
determined in ten microscopic field areas and compared with untreated cells. Data are expressed as mean ± SE of three independent
experiments. (e) HO-1 protein expression was analyzed by immunoblot and normalized to GAPDH. A representative image of three
independent experiments is shown. (f) CTR mRNA levels were measured by RT-PCR after 4 days and normalized to β-actin. Results are
shown as mean ± SE from three independent experiments. (g, h) Bone marrow-derived macrophages (BMDMs) were isolated from wild
type (HO-1+/+) and HO-1 knock down (HO-1−/−) mice and grown in culture medium with 50 ng/mLM-CSF or in osteoclastogenic medium
(50 ng/mLM‐CSF + 100 ng/mLRANKL) in the presence or absence of FHb (10 μmol/L heme group) for 5 days. RNA levels of HO-1 (g)
and CTR (h) were measured by RT-PCR and normalized to β-actin. Results are shown as mean ± SE from three independent experiments.
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inhibitory effect of FHb was dose-dependent, occurred even at
low micromolar concentrations and was not associated with
cell death. To explore the signaling events downstream of
RANK in response to RANKL and FHb, we analyzed the key
proteins involved in osteoclastogenesis. Previous studies have
revealed that TRAF6 is essential in the cytoskeletal organiza-
tion and resorptive activity of OC [12].Mitogen-activated pro-
tein kinases (MAPKs), such as JNK and p38, are critical for
normal osteoclastogenic differentiation and activation [13,
14]. NFκB, together with c-Fos, is also important determinants
of OC formation [15, 16]. Here, we showed that FHb
blunted early signaling events of osteoclastogenesis involv-
ing MAPK and NFκB activation as well as c-Fos and
TRAF-6, thereby blocking the osteoclastogenic reprogram-
ming of macrophages.
Previously, it was demonstrated that heme inhibits osteo-
clastogenesis as well as the expression of OC marker genes
such as TRAP, CTR, and DC-STAMP via the induction of
HO-1, a key enzyme of heme catabolism [40]. We have
reported that MetHb but not ferrous Hb releases its heme
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Figure 5: FHb inhibits RANK-RANKL interaction. RAW264.7 cells were grown in control growth media or in osteoclastogenic media
(control growth medium supplemented with 50 ng/mL RANKL) in the absence or presence of FHb (10 μmol/L heme group) for 3 or 5
days (a–e). (a) RANK mRNA levels were measured after 3 days by qRT-PCR and normalized to β-actin. Results are shown as mean ± SE
from three independent experiments. (b) RANK protein expression was analyzed by immunoblot after 3 days and normalized to GAPDH.
A representative image from four independent experiments is shown. (c) Densitometric analysis of RANK immunoblots is shown as
mean ± SE from four independent experiments. (d) Cell association of RANKL was analyzed after 5 days by immunoblot specific to
RANKL and normalized to GAPDH. (e) Densitometric analysis of RANKL immunoblots is shown as mean ± SE from three
independent experiments. (f) RANK was immunoprecipitated from cell lysates and coincubated with 6 × His RANKL (1 μg) in the
presence or absence of FHb (10 μmol/L heme group) for 1 hr. RANK-RANKL interaction was analyzed by immunoblot.
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Figure 6: FHb inhibits RANKL-induced signaling pathways involved in OC differentiation. RAW264.7 cells were cultured on 24-well plates
(for immunofluorescent staining) or 6-well plates (for immunoblot) in control growth media or in osteoclastogenic media (control growth
media supplemented with 50 ng/mL RANKL) with or without FHb (10 μmol/L). (a) TRAF-6 expression was analyzed by immunoblot
after 2 days. (b) p38 and JNK phosphorylation were assessed at 40min and normalized to p38, JNK, and GAPDH. (c) c-Fos activation
was analyzed after 40min and normalized to GAPDH. (d) Nuclear translocation of NFκB was analyzed after 40min from isolated nuclei
and normalized to Lamin B1. (e, f) NFATc1 expression and nuclear translocation were analyzed by immunoblot and normalized to
HSP90 (cytosolic protein) and Lamin B1 (nuclear protein). (g, h) NFATc1 expression and nuclear translocation were analyzed by
immunofluorescence after 24 hrs. Results are shown as mean ± SE from three independent experiments.
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Figure 7: FHb is present in hemorrhagic calcified arteries and impairs OLCs formation. (a) Representative spectral scan of human tissue
specimens derived from healthy carotid arteries, calcified atheromas, and calcified atheromas with hemorrhage. Spectophotometric
determination of oxidized Hb was measured from 500 to 700 nm wavelengths. (b) Representative immunoblot (one out of three
performed) demonstrates Hb oxidation in human vessels from two healthy arteries, two calcified atheromas, and two calcified atheromas
with hemorrhage (20 μg/lane). (c) Histological pattern analysis of healthy carotid arteries (left), calcified plaques (middle), and calcified
lesions with hemorrhage (right). Basic histological architecture and cellular components are stained with H&E staining showing
extravascular red blood cells in the calcified atheroma with hemorrhage (row A). Calcium deposits are visualized by Von Kossa staining
(row B). The presence of FHb is showed by immunohistochemistry (row C). CD68-positive multinucleated giant cells (row D) were
specified as OLCs with immunohistochemical staining specific to OC marker TRAP (row E) and cathepsin K (row F).
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prosthetic group that is taken up by endothelial cells followed
by the activation of HO-1 [57]. Here, we demonstrated that
FHb induced catalytically active HO-1 supposing that its
heme group could be responsible for the inhibition of
osteoclastogenesis [40]. Furthermore, others have demon-
strated that deltamethrin, a pyrethroid pesticide or magnolol,
an extract with anti-inflammatory properties isolated from
Magnolia officinalis prevents OC formation in a HO-1
dependent fashion [58, 59]. These observations underscore
the inhibitory effects of HO-1 in osteoclastogenesis. How-
ever, our results presented here showed that the inhibitory
effect of FHb on OC formation was independent of HO-1.
This notion was also corroborated by using murine BMDMs
derived from HO-1−/− that indicated other mechanisms are
involved in FHb-mediated inhibition of OC formation that
are independent of HO enzyme activity.
RANK and RANKL interaction is essential for OC for-
mation, and RANK expression is vital for the differentiation
of myeloid-derived OCs [7, 37, 54] as evidenced by the lack
of OC differentiation in RANK(−/−) mice [60]. Our study pro-
vides evidence that FHb can attenuate RANKL-induced
RANK expression in RAW264.7 cells suggesting a possible
mechanism by which FHb impairs OC differentiation from
macrophages.
Osteoprotegerin (OPG) is a decoy receptor for RANKL
and plays a regulatory role in bone resorption by inhibiting
OC function [61]. As a dimer, OPG competes with RANK
for RANKL binding and effectively inhibits RANK-RANKL
interaction [62]. Here, by demonstrating the decrease of
RANKL interaction with RANK in RAW264.7 cells, we pro-
vide an additional potential explanation for the involvement
of FHb in the impairment of OC differentiation. This obser-
vation was corroborated by our test tube experiments, which
support the hypothesis that FHb directly hinders RANK-
RANKL interaction. Our results suggest that FHb inhibits
OC formation in an OPG-like manner by directly inhibiting
RANK-RANKL interaction. The exact mechanism of such
interaction requires further investigations.
5. Conclusions
In summary, we provide evidence for the involvement of
FHb in the inhibition of osteoclastogenesis (Figure 8). This
effect of FHb suggests that the presence of FHb in hemor-
rhagic atheromas might create a unique microenvironment
where OLC-mediated resorption of calcium deposits is
impaired that blocks the endogenous calcium resorption
capability in the vasculature.
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Figure 8: (a) FHb inhibits RANK-RANKL interaction and blocks osteoclastogenic signalization pathways downstream of RANK such as
tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), c-Jun N-terminal kinase (JNK), p38, c-Fos, and receptor activator of
nuclear factor-kappa B (NFκB), thereby preventing the expression and nuclear translocation of nuclear factor of activated T-cells,
cytoplasmic 1 (NFATc1), and subsequent expression of OC-specific genes. (b) FHb, which is abundantly present in hemorrhagic calcified
lesions, impedes the formation of OCs from macrophages disturbing OC bone resorption activity by downregulating OC-specific gene
expression such as NFATc1, DC-STAMP, TRAP, CatK, and CTR. During vascular calcification, smooth muscle cells in the vessel walls
undergo osteochondrogenic reprogramming and produce RANKL, which initiates OC formation from macrophages as a potential
compensatory mechanism to remove calcium deposits. However, the presence of FHb in hemorrhagic atheromas might create a unique
microenvironment where OLCs-mediated resorption of calcium deposits is impaired, thereby blocking the endogenous calcium resorption
capability in the vasculature.
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Supplementary Materials
Supplementary Figure 1: RAW264.7 cells were cultured in
control growth media or in osteoclastogenic media (control
growth media supplemented with 50 ng/mL RANKL) in the
absence or presence of FHb (10μmol/L heme group) for 4
days. (A) Cell proliferation and viability were analyzed with
MTT 38 assay at various time points (one to four days). (B)
Caspase-3 cleavage was analyzed after 4 days with immuno-
blot. Supplementary Figure 2: Recombinant 6×His-tagged
RANKL was expressed in E. coli Rosetta 2. (A) Purity of
recombinant RANKL was analyzed by Coomassie-staining
(left panel) and immunoblot (right panel). (B) RAW264.7
cells were cultured in control growth media or in osteoclasto-
genic medium (using 6×His-tagged RANKL) with or with-
out FHb (10μmol/L heme group) for 5 days. Biological
activity of 6×His-tagged RANKL was verified by TRAP
staining. RANK was immunoprecipitated from RAW264.7
cell lysates and coincubated with His-tagged recombinant
RANKL (1μg) in the presence of absence of FHb. The asso-
ciation of recombinant RANKL with RANK was analyzed
by immunoblot. (Supplementary Materials)
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